Methylphenobarbital

DB00849

small molecule approved

Deskripsi

A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.

Struktur Molekul 2D

Berat 246.2619
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 34 (range 11-67) hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract.

Metabolisme

Hepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1529 Data
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Methylphenobarbital.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Methylphenobarbital.
Buprenorphine Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Hydrocodone Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Magnesium sulfate The therapeutic efficacy of Methylphenobarbital can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Methylphenobarbital may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Mirtazapine Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Orphenadrine Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Pramipexole Methylphenobarbital may increase the sedative activities of Pramipexole.
Ropinirole Methylphenobarbital may increase the sedative activities of Ropinirole.
Rotigotine Methylphenobarbital may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Methylphenobarbital.
Suvorexant Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.
Thalidomide Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Amphetamine.
Phentermine The serum concentration of Methylphenobarbital can be decreased when it is combined with Phentermine.
Pseudoephedrine The serum concentration of Methylphenobarbital can be decreased when it is combined with Pseudoephedrine.
Benzphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Benzphetamine.
Diethylpropion The serum concentration of Methylphenobarbital can be decreased when it is combined with Diethylpropion.
Lisdexamfetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Lisdexamfetamine.
Mephentermine The serum concentration of Methylphenobarbital can be decreased when it is combined with Mephentermine.
MMDA The serum concentration of Methylphenobarbital can be decreased when it is combined with MMDA.
Midomafetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Midomafetamine.
2,5-Dimethoxy-4-ethylamphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with 2,5-Dimethoxy-4-ethylamphetamine.
4-Bromo-2,5-dimethoxyamphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with 4-Bromo-2,5-dimethoxyamphetamine.
Tenamfetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Tenamfetamine.
Chlorphentermine The serum concentration of Methylphenobarbital can be decreased when it is combined with Chlorphentermine.
Methylenedioxyethamphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Methylenedioxyethamphetamine.
Dextroamphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Dextroamphetamine.
Metamfetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Metamfetamine.
Iofetamine I-123 The serum concentration of Methylphenobarbital can be decreased when it is combined with Iofetamine I-123.
Ritobegron The serum concentration of Methylphenobarbital can be decreased when it is combined with Ritobegron.
Mephedrone The serum concentration of Methylphenobarbital can be decreased when it is combined with Mephedrone.
Methoxyphenamine The serum concentration of Methylphenobarbital can be decreased when it is combined with Methoxyphenamine.
Gepefrine The serum concentration of Methylphenobarbital can be decreased when it is combined with Gepefrine.
2,5-Dimethoxy-4-ethylthioamphetamine The serum concentration of Methylphenobarbital can be decreased when it is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
Phendimetrazine The serum concentration of Methylphenobarbital can be decreased when it is combined with Phendimetrazine.
Dabrafenib The serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Methylphenobarbital.
Luliconazole The serum concentration of Methylphenobarbital can be increased when it is combined with Luliconazole.
Mefloquine The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mefloquine.
Orlistat Orlistat can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetaminophen The metabolism of Acetaminophen can be increased when combined with Methylphenobarbital.
Propacetamol The metabolism of Propacetamol can be increased when combined with Methylphenobarbital.
Chloramphenicol The metabolism of Methylphenobarbital can be decreased when combined with Chloramphenicol.
Doxycycline The serum concentration of Doxycycline can be decreased when it is combined with Methylphenobarbital.
Griseofulvin The serum concentration of Griseofulvin can be decreased when it is combined with Methylphenobarbital.
Mianserin The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mianserin.
Butalbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butalbital.
Pentobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pentobarbital.
Secobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Secobarbital.
Methohexital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methohexital.
Thiopental The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiopental.
Thiamylal The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.
Amobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.
Hexobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hexobarbital.
Barbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.
Barbexaclone The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbexaclone.
Pyridoxine The metabolism of Methylphenobarbital can be increased when combined with Pyridoxine.
Teniposide The serum concentration of Teniposide can be decreased when it is combined with Methylphenobarbital.
Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Methylphenobarbital.
Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Methylphenobarbital.
Metyrapone The serum concentration of Metyrapone can be decreased when it is combined with Methylphenobarbital.
Topotecan Methylphenobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide The serum concentration of Methylphenobarbital can be decreased when it is combined with Acetazolamide.
Valproic acid The serum concentration of Phenobarbital, an active metabolite of Methylphenobarbital, can be increased when used in combination with Valproic acid.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Methylphenobarbital.
Sodium oxybate Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Methylphenidate The serum concentration of Methylphenobarbital can be increased when it is combined with Methylphenidate.
Dexmethylphenidate The serum concentration of Methylphenobarbital can be increased when it is combined with Dexmethylphenidate.
Quinine The serum concentration of Methylphenobarbital can be increased when it is combined with Quinine.
Quinidine The serum concentration of Methylphenobarbital can be increased when it is combined with Quinidine.
Lamotrigine Methylphenobarbital may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Methylphenobarbital.
Perampanel The metabolism of Perampanel can be increased when combined with Methylphenobarbital.
Warfarin The metabolism of Warfarin can be increased when combined with Methylphenobarbital.
Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Methylphenobarbital.
(R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Methylphenobarbital.
R,S-Warfarin alcohol The metabolism of R,S-Warfarin alcohol can be increased when combined with Methylphenobarbital.
S,R-Warfarin alcohol The metabolism of S,R-Warfarin alcohol can be increased when combined with Methylphenobarbital.
(S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Methylphenobarbital.
Cobicistat The serum concentration of Cobicistat can be decreased when it is combined with Methylphenobarbital.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Methylphenobarbital.
Etravirine The metabolism of Etravirine can be increased when combined with Methylphenobarbital.
Felbamate The serum concentration of Phenobarbital, an active metabolite of Methylphenobarbital, can be increased when used in combination with Felbamate.
Boceprevir The serum concentration of Boceprevir can be decreased when it is combined with Methylphenobarbital.
Canagliflozin The serum concentration of Canagliflozin can be decreased when it is combined with Methylphenobarbital.
Deferasirox The serum concentration of Deferasirox can be decreased when it is combined with Methylphenobarbital.
Lacosamide The metabolism of Lacosamide can be increased when combined with Methylphenobarbital.
Stiripentol The serum concentration of Stiripentol can be decreased when it is combined with Methylphenobarbital.

Target Protein

Gamma-aminobutyric acid receptor subunit alpha-2 GABRA2
Gamma-aminobutyric acid receptor subunit alpha-3 GABRA3
Gamma-aminobutyric acid receptor subunit alpha-4 GABRA4
Gamma-aminobutyric acid receptor subunit alpha-5 GABRA5
Gamma-aminobutyric acid receptor subunit alpha-6 GABRA6
Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1
Neuronal acetylcholine receptor subunit alpha-4 CHRNA4
Neuronal acetylcholine receptor subunit alpha-7 CHRNA7
Glutamate receptor 2 GRIA2
Glutamate receptor ionotropic, kainate 2 GRIK2
Nuclear receptor subfamily 1 group I member 2 NR1I2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 5 • International brands: 5
Produk
  • Mebaral
    Tablet • 32 mg/1 • Oral • US
  • Mebaral
    Tablet • 50 mg/1 • Oral • US
  • Mebaral
    Tablet • 100 mg/1 • Oral • US
  • Mephobarbital
    Tablet • 50 mg/1 • Oral • US
  • Mephobarbital
    Tablet • 100 mg/1 • Oral • US
International Brands
  • Mephyltaletten
  • Phemiton
  • Phemitone
  • Phenmiton
  • Prominal

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul